[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pgt-a\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pgt-a":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,82,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100636796","comparison-of-two-types-of-calcium-ca-ionophore-treatments-for-oocyte-activation-in-cases-of-suboptimal-fertilization-potential-100636796",false,"NCT07570342","Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential","(Ca²⁺)","Inclusion Criteria:\n\n1. Patients undergoing assisted reproductive technology cycles when ICSI is indicated.\n2. Patients with a minimum of 3 MII oocytes after denudation.\n3. Maternal age 18-43 years old.\n4. PGT-A cycles with only trophectoderm biopsies on day 5\u002F6\u002F7.\n5. BMI\\\u003C35.\n6. Fresh and frozen immotile ejaculated sperm.\n7. Fresh and frozen TESE sperm (motile and immotile).\n8. Globozoospermia.\n\n10\\. Couples undergoing ICSI due to poor fertilization history (≤30%), or previous fertilization failure.\n\nExclusion Criteria:\n\n1. PGT-M\u002FSR cycles.\n2. Fresh and frozen motile ejaculated \u002F FNA sperm.\n3. IVF inseminated oocytes.",true,"FEMALE","18 Years","43 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to investigate the effectiveness and safety of assisted oocyte activation (AOA) using Ca²⁺ ionophores in cases of total fertilization failure (TFF) due to oocyte activation deficiency (OAD). The study will be conducted in two phases: Phase I will compare the fertilization rates of oocytes exposed to two types of Ca²⁺ ionophore treatments- Ionomycin solution and commercially available CultActive-against a control group without calcium ionophore treatment. Phase II will assess whether an additional injection of CaCl2, prior to exposure to the chosen ionophore from Phase I, further improves fertilization outcomes. The goal is to identify the optimal AOA protocol for improving fertilization rates and to evaluate the safety and efficacy of this approach in relation to ploidy, with a focus on ensuring normal pre-implantation embryo development.",[28,29,30,31],"ICSI","Testicular Sperm Extraction in Azoospermic Patients","Male Infertility","PGT-A",[28,31,33,34,35,36,37,38,39],"artificial oocyte activation","AOA","calcium ionophore","ionomycin","TESE","Immotile sperm","Failed fertilization","NOT_YET_RECRUITING","2026-05-06",{"date":43,"type":44},"2026-05-11","ACTUAL",{"date":46,"type":22},"2026-04-30",{"date":48,"type":22},"2026-12-31",{"name":50,"class":51},"ART Fertility Clinics LLC","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100584326","pims-vs-pgt-a-in-infertile-pcos-patients-100584326","NCT06887881","PIMS vs PGT-A in Infertile PCOS Patients","Clinical Use of Preimplantation DNA Methylation Screening (PIMS) and Preimplantation Genetics Screening (PGT-A) in Infertile PCOS Patients-A Multicenter, Prospective Randomized Non-inferior Clinical Trial","Inclusion Criteria:\n\n1. Women aged between 20 and 40 years diagnosed with PCOS according to international evidence-based guidline for assessment and management of policystic ovarian syndrome 2018.\n2. Women who plan to undergo the 1st\u002F2nd IVF\u002FICSI\u002FPGT-A treatment cycle.\n3. Women who obtain 2 or more blastocysts that have morphological score of 4BC\u002F4CB or better on Day 5of embryo culture.\n4. Culture all the cleavage stage embryos into blastocysts, conduct biopsy on all the blastocysts, and cryopreserve each blastocyst as a single embryo\n5. Agree to the thawing and transfer of a single blastocyst.\n6. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus unicornate, bicornate, or duplex); untreated uterine septum, submucous myoma, or endometrial polyp(s); or with history of intrauterine adhesions.\n2. Women who are indicated and planned to undergo preimplantation genetic testing for structural rearrangements (PGT-SR) or preimplantation genetic testing for monogenic (PGT-M).\n3. Women who use donated oocytes or sperm to achieve pregnancy.\n4. Women with contraindication for assisted reproductive technology or for pregnancy, such as undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected carcinoma including including cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding and so on.\n5. Untreated hydrosalpinx according to ultrasonography test.","20 Years","40 Years",{"count":62,"type":22},766,[25],"This experiment has become a serious issue for two reasons: DNA methylation plays an important role during embryogenesis, global abnormal methylome reprogramming often occurs in human embryos, and DNA methylome pattern is associated with live birth rate. The endocrine metabolic disorders of polycystic ovarian syndrome (PCOS) patients may affect the epigenetic status of embryos and lead to the increase of early pregnancy loss rate in PCOS patients. However, there is still no technology using DNA methylome as an indicator in preimplantation embryo screening in PCOS patients. Our recent study showed that using Pre-implantation Methylation Screening (PIMS) can select embryos with better methylation state and euploid chromosomes. The efficiency of PIMS in PCOS patients needs further validation through randomized controlled clinical trial.\n\nThe purpose of the study is to compare whether the two groups of PCOS patients who selected embryos using PIMS and selected embryos using \"PGT-A + morphology\"had any difference in early pregnancy loss rate. This study aims to explore whether PIMS can be used as another embryo evaluation method besides \"PGT-A+morphology\" to screen good developmental potential embryos in patients with PCOS. Investigators need to clarify whether a better embryo evaluation system can be established through PIMS technology during assisted reproductive treatment for infertile PCOS couples and provide credible and effective evidence-based medical evidence for the application of PMIS technology in the field of reproductive medicine.",[31,66,67],"PCOS","PIMS",[67,66,31,69,70],"cumulative live birth rate","early pregnancy loss rate","RECRUITING","2026-03-29",{"date":74,"type":44},"2026-04-02",{"date":76,"type":44},"2025-06-12",{"date":78,"type":22},"2028-12",{"name":80,"class":51},"First Affiliated Hospital, Sun Yat-Sen University",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":88,"minAge":4,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":81},"100600140","evaluating-the-utility-of-implementing-microfluids-for-sperm-preparation-compared-to-conventional-method-of-density-gradient-centrifugation-in-a-pgt-a-program-a-sibling-oocyte-study-100600140","NCT07093619","Evaluating the Utility of Implementing Microfluids for Sperm Preparation Compared to Conventional Method of Density Gradient Centrifugation in a PGT-A Program: a Sibling Oocyte Study","Inclusion Criteria:\n\n1. Women with at least 8 MII per cycle after denudation (AFC≥8).\n2. Women of all ages.\n3. All embryo qualities ≥BL3CC at the time of biopsy on day 5, 6 and\u002For 7.\n4. Fresh sperm used from ejaculate with a concentration ≥1 mill\u002Fml and ≥10% motility (A+B).\n5. Sperm samples with a minimum of 2 ml.\n\nExclusion Criteria:\n\n* Frozen oocytes samples with severe oligospermia (≤1mill\u002Fml).\n* PGT-M cases\n* Sperm with \\> 1M\u002Fml of round cells","ALL",{"count":90,"type":22},100,[25],"In assisted reproductive technology (ART), sperm preparation aims to select the most viable sperm for ICSI. Unlike conventional methods like density gradients or sperm washing, microfluidic techniques mimic natural selection in the female reproductive tract by using laminar flow without centrifugation, reducing the risk of DNA damage. This method isolates highly motile sperm while filtering out debris and immotile cells. Studies show that microfluidics improve embryo quality, increase pregnancy rates, and may lead to higher euploidy rates. Additional benefits include improved safety, scalability, and shorter preparation times.",[94,28,31],"Semen Analysis",[96,97,98,99,100,101],"IVF","Sperm Preparation","euploid","fertilization rate","blastulation rate","morphokinetics","2025-09-30",{"date":104,"type":44},"2025-10-02",{"date":106,"type":44},"2025-09-12",{"date":108,"type":22},"2026-12-30",{"name":50,"class":51},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":121,"conditions":122,"keywords":129,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100565054","phase-4-protocol-with-progestin-primed-ovarian-stimulation-ppos-from-the-beginning-of-stimulation-versus-protocol-with-gnrh-antagonists-for-ovarian-stimulation-in-patients-undergoing-duostim-with-embryo-accumulation-for-pgt-a-100565054","NCT06637189","Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.","PPDUO","Inclusion Criteria:\n\n* Regular menstrual cycles between 21 and 35 days, inclusive.\n* Indication of IVF with PGT-A.\n* Both ovaries present.\n* Ability to participate and complete the study.\n* Give and sign the consent to participate in the study.\n\nExclusion Criteria:\n\n* Endometriosis grade III\u002FIV\n* Concurrent participation in another study",{"count":118,"type":22},144,[120],"PHASE4","The PPOS protocol (Progestin-primed Ovarian Stimulation) involves avoiding ovulation during ovarian stimulation with progesterone. It is a reliable and safe protocol that has been widely used in recent years for in vitro fertilization, as it reduces the number of injections needed during controlled ovarian stimulation and is more cost-effective for patients.\n\nThe aim of this study is to compare two methods of ovarian stimulation for in vitro fertilization: the PPOS protocol (Group A) and the conventional protocol with injected antagonists (Group B). The goal is to determine whether both methods are equally effective in obtaining euploid embryos in the context of double ovarian stimulation.",[123,124,125,126,127,128,31],"Stimulation in the Ovary","Embryo","Oocyte","Oocyte Retrieval","Fertilization in Vitro","Blastocyst",[130,131,132,133,31],"duostim","ovarian stimulation","progesterone","GnRH antagonists","2024-10-10",{"date":136,"type":44},"2024-10-15",{"date":136,"type":22},{"date":139,"type":22},"2025-12-31",{"name":141,"class":51},"Ginefiv"]